Key concerns about the current state of bladder cancer: A position paper from the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic Oncology

Cancer

Volumn 115, Issue 18, 2009, Pages 4096-4103

  Lotan, Yair ^a   Kamat, Ashish M ^b   Porter, Michael P ^c   Robinson, Victoria L ^d   Shore, Neal ^e   Jewett, Michael ^f   Schelhammer, Paul F ^g   White, Ralph DeVere ^h   Quale, Diane ⁱ   Lee, Cheryl T ^j  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e Grand Strand Urology   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

^g UNIVERSITY OF VIRGINIA   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ Bladder Cancer Advocacy Network   (United States)

^j UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

more..

Author keywords

Advocacy; Bladder cancer; Concerns; Funding

Indexed keywords

BLADDER CANCER; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL FEATURE; FUNDING; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH CARE PERSONNEL; MEDICAL EDUCATION; PREVALENCE; PRIORITY JOURNAL; REVIEW;

BIOMEDICAL RESEARCH; FINANCING, GOVERNMENT; HEALTH CARE COSTS; HEALTH EDUCATION; HUMANS; PATIENT ADVOCACY; URINARY BLADDER NEOPLASMS; UROLOGY;

EID: 70149120096     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24463     Document Type: Review

References (19)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Ries LAG, Melbert D, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2004. Bethesda, MD: National Cancer Institute; 2007
3. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics. 2003;21:1315-1330. (Pubitemid 38041357)
4. Zeegers MP, Tan FE, Dorant E, van Den Brandt PA. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer. 2000;89:630-639. (Pubitemid 30640110)
5. Samanic C, Kogevinas M, Dosemeci M, et al. Smoking and bladder cancer in Spain: effects of tobacco type, timing, environmental tobacco smoke, and gender. Cancer Epidemiol Biomarkers Prev. 2006;15:1348-1354. (Pubitemid 44125293)
6. Nieder AM, Lotan Y, Nuss GR, et al. Are patients with hematuria appropriately referred to Urology? A multi-institutional questionnaire based survey. Urol Uncol. In press.
7. Johnson EK, Daignault S, Zhang Y, Lee CT. Patterns of hematuria referral to urologists: does a gender disparity exist? Urology. 2008;72:498-502; discussion 502-503.
8. Singh R, Saleemi A, Walsh K, Popert R, O'Brien T. Near misses in bladder cancer-an airline safety approach to urology. Ann R Coll Surg Engl. 2003;85:378-381. (Pubitemid 37390937)
9. Wallace DM, Raghavan D, Kelly KA, et al. Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol. 1991;67:608-615.
10. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
11. Riley GF, Potosky AL, Lubitz JD, Kessler LG. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care. 1995;33:828-841.
12. Cooksley CD, Avritscher EB, Grossman HB, et al. Clinical model of cost of bladder cancer in the elderly. Urology. 2008;71:519-525.
13. A broken pipeline? Flat funding of the NIH puts a generation of science at risk. Available at: http://www.brokenpipeline.org/ Accessed October 2008.
14. Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer. 2005;5:713-725.
15. Crallan RA, Georgopoulos NT, Southgate J. Experimental models of human bladder carcinogenesis. Carcinogenesis. 2006;27:374-381. (Pubitemid 43378894)
16. National Cancer Institute. Cancer trends progress report 2007 update. Available at: http://progressreport.cancer.gov/ Accessed October 2008.
17. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. 1976. J Urol. 2002;167(2 pt 2):891-893; discussion 893-895.
18. Sternberg CN, Yagoda A, Scher HI, et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol. 1985;133:403-407. (Pubitemid 15129797)
19. Brower V. The squeaky wheel gets the grease. Research funding is not necessarily allocated to those who need it most. EMBO Rep. 2005;6:1014-1017.